ORMP
Price:
$2.39
Market Cap:
$97.44M
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its n...[Read more]
Industry
Biotechnology
IPO Date
2007-05-01
Stock Exchange
NASDAQ
Ticker
ORMP
According to Oramed Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 4.69. This represents a change of -129.22% compared to the average of -16.05 of the last 4 quarters.
The mean historical PE Ratio of Oramed Pharmaceuticals Inc. over the last ten years is -11.02. The current 4.69 PE Ratio has changed -4354.40% with respect to the historical average. Over the past ten years (40 quarters), ORMP's PE Ratio was at its highest in in the May 2019 quarter at -3.22. The PE Ratio was at its lowest in in the February 2014 quarter at -30.42.
Average
-11.02
Median
-9.70
Minimum
-25.19
Maximum
-4.04
Discovering the peaks and valleys of Oramed Pharmaceuticals Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 304.72%
Maximum Annual PE Ratio = -4.04
Minimum Annual Increase = -50.69%
Minimum Annual PE Ratio = -25.19
Year | PE Ratio | Change |
---|---|---|
2022 | -12.42 | -50.69% |
2021 | -25.19 | 304.72% |
2020 | -6.23 | 54.21% |
2019 | -4.04 | -30.26% |
2018 | -5.79 | -47.31% |
2017 | -10.99 | 32.32% |
2016 | -8.30 | -1.27% |
2015 | -8.41 | -48.90% |
2014 | -16.46 | 32.51% |
2013 | -12.42 | 83.81% |
The current PE Ratio of Oramed Pharmaceuticals Inc. (ORMP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-14.61
5-year avg
-10.73
10-year avg
-11.02
Oramed Pharmaceuticals Inc.’s PE Ratio is greater than Protalix BioTherapeutics, Inc. (-6.39), greater than Corvus Pharmaceuticals, Inc. (-23.81), greater than Aldeyra Therapeutics, Inc. (-8.13), greater than Gamida Cell Ltd. (-0.23), greater than Checkpoint Therapeutics, Inc. (-3.00), greater than BioLineRx Ltd. (-1.13), greater than Ardelyx, Inc. (-19.14), greater than Lexicon Pharmaceuticals, Inc. (-1.87), greater than Seres Therapeutics, Inc. (-0.75), greater than ImmunityBio, Inc. (-5.98), less than X4 Pharmaceuticals, Inc. (6.04), greater than Mereo BioPharma Group plc (-16.88), greater than Inozyme Pharma, Inc. (-3.09), greater than Terns Pharmaceuticals, Inc. (-5.51), greater than Leap Therapeutics, Inc. (-2.39), greater than Zura Bio Limited (-10.87), greater than Altamira Therapeutics Ltd. (-0.03), greater than Immix Biopharma, Inc. (-2.39), greater than Enveric Biosciences, Inc. (-0.33), greater than Palisade Bio, Inc. (-0.24), greater than Hepion Pharmaceuticals, Inc. (-0.13), greater than AVROBIO, Inc. (2.07), greater than CohBar, Inc. (-0.12), greater than Ocean Biomedical, Inc. (-0.88), greater than Elevation Oncology, Inc. (-0.78),
Company | PE Ratio | Market cap |
---|---|---|
-6.39 | $94.13M | |
-23.81 | $564.21M | |
-8.13 | $307.80M | |
-0.23 | $4.34M | |
-3.00 | $154.67M | |
-1.13 | $37.41M | |
-19.14 | $1.40B | |
-1.87 | $435.60M | |
-0.75 | $137.42M | |
-5.98 | $3.62B | |
6.04 | $89.59M | |
-16.88 | $616.59M | |
-3.09 | $277.29M | |
-5.51 | $599.50M | |
-2.39 | $140.43M | |
-10.87 | $278.69M | |
-0.03 | $1.96M | |
-2.39 | $43.37M | |
-0.33 | $4.14M | |
-0.24 | $3.70M | |
-0.13 | $3.68M | |
2.07 | $5.24M | |
-0.12 | $1.42M | |
-0.88 | $31.18M | |
-0.78 | $30.89M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oramed Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Oramed Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Oramed Pharmaceuticals Inc.'s PE Ratio?
How is the PE Ratio calculated for Oramed Pharmaceuticals Inc. (ORMP)?
What is the highest PE Ratio for Oramed Pharmaceuticals Inc. (ORMP)?
What is the 3-year average PE Ratio for Oramed Pharmaceuticals Inc. (ORMP)?
What is the 5-year average PE Ratio for Oramed Pharmaceuticals Inc. (ORMP)?
How does the current PE Ratio for Oramed Pharmaceuticals Inc. (ORMP) compare to its historical average?